Bionano Genomics, Inc.

Bionano Genomics, Inc. operates in the genome analysis solutions industry, providing optical genome mapping (OGM) solutions, nucleic acid extraction and purification systems, diagnostic services, and software. The company's mission is to transform genome analysis through these offerings. The worldwide market for genomics products and services is estimated to reach approximately $85.1 billion by 2030, growing from approximately $44.5 billion in 2024, representing a compound annual growth rate of 12.6% ¹. The company anticipates OGM adoption in cytogenomics, discovery research, and cell and gene therapy applications. There are an estimated 10,000 cytogenetic labs globally (excluding India and developing countries) that analyze approximately 10.0 million samples per year ². Additionally, about 1,400 pharmaceutical and biotech companies are involved in cell therapy R&D that utilize cytogenetics methods ³. The economic potential for OGM in these markets is approximately $10.0 billion annually, with $3.0 billion attributed to cell and gene therapy applications ⁴. The clinical NGS market, which the company's platform-agnostic software solution addresses, is estimated at approximately $4.1 billion in 2025 and is projected to grow to approximately $8.2 billion in 2029, at an 18.8% compound annual growth rate ⁵.

The company's core business model revolves around generating revenue from the sale of OGM and Ionic Purification systems and consumables, VIA software subscriptions, and diagnostic testing services through Bionano Laboratories. Revenue is a mix of transactional income from instrument and consumable sales and recurring income from software subscriptions and services. Primary customer segments include academic and governmental research institutions, academic and commercial clinical laboratories, and biopharmaceutical and contract research companies. The company aims to create an end-to-end OGM solution, from DNA isolation to data analysis, leveraging both organically developed solutions and third-party partnerships.

Bionano's product and service lines include OGM systems, nucleic acid isolation and purification systems, software solutions, and testing and laboratory services. The OGM systems, Saphyr and Stratys, deliver OGM data for ultra-sensitive and ultra-specific detection of structural variations (SV). These systems are used in genetic disease, cancer, and cell and gene therapy applications. The OGM workflow involves DNA isolation, DNA labeling, DNA mapping, data processing, and data analysis. The Ionic Purification system, utilizing isotachophoresis (ITP) technology, extracts and purifies high-quality DNA or RNA from various sample types, addressing the need for ultra-high molecular weight (UHMW) DNA in OGM applications. The VIA software provides genomic data interpretation solutions for research use in cytogenomics and molecular pathology labs, integrating OGM, NGS, and microarray data.

Bionano Laboratories offers an OGM-based laboratory developed test (LDT) for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and provides OGM-based testing services for research applications. During 2024, Bionano Laboratories phased out certain testing services for neurodevelopmental disorders (NDDs), including autism spectrum disorders (ASDs) and other childhood development disorders. In 2025, the offering of OGM-based LDT tests for hematological malignancies and pre- and postnatal constitutional genetic disorders was also phased out.

For the fiscal year ended December 31, 2025, total revenue decreased by $2.268 million, or 7%, to $28.508 million ⁶ compared to $30.776 million in 2024 ⁷. Product revenue was $26.743 million ⁸, a decrease of $265,000 or 1% from $27.008 million in 2024 ⁹. Service and other revenue decreased by $2.003 million, or 53%, to $1.765 million ¹⁰ from $3.768 million in 2024 ¹¹. The company reported a net loss of $26.395 million ¹² for 2025, a significant improvement from the $112.017 million net loss in 2024 ¹³. Diluted EPS was $(4.85) ¹⁴ in 2025, compared to $(88.13) in 2024 ¹⁵. Cash and cash equivalents were $2.990 million ¹⁶ as of December 31, 2025, with short-term investments of $16.279 million ¹⁷ and restricted cash and investments of $10.266 million ¹⁸. Total current liabilities were $22.942 million ¹⁹, and convertible debentures payable (at fair value) were $9.979 million ²⁰.

Year-over-year, instrument revenue decreased by $1.680 million, or 21%, to $6.363 million ²¹ in 2025 from $8.043 million in 2024 ²². This was due to a decrease in the number of OGM and Ionic instruments sold. The installed base of OGM systems grew to 387 as of December 31, 2025, an increase of approximately 4.3% from 371 as of December 31, 2024 ²³. Consumables revenue increased by $1.197 million, or 9%, to $13.970 million ²⁴ in 2025 from $12.773 million in 2024 ²⁵, driven by an increase in the average selling price of flowcells, partially offset by manufacturing delays. Software revenue increased by $218,000, or 4%, to $6.410 million ²⁶ in 2025 from $6.192 million in 2024 ²⁷, due to an increase in VIA software licenses sold. Cost of product revenue decreased by $14.020 million, or 49%, to $14.429 million ²⁸ in 2025 from $28.449 million in 2024 ²⁹, primarily due to the absence of $9.8 million in inventory-related charges recorded in 2024. Total gross profit increased by $12.805 million, or 3370%, to $13.185 million ³⁰ in 2025 from $380,000 in 2024 ³¹, with product gross margin improving to 46% ³² from (5)% in 2024 ³³. Research and development expenses decreased by $13.429 million, or 54%, to $11.374 million ³⁴ in 2025 from $24.803 million in 2024 ³⁵, mainly due to headcount reductions and lower professional and consulting fees. Selling, general and administrative expenses decreased by $16.705 million, or 32%, to $35.150 million ³⁶ in 2025 from $51.855 million in 2024 ³⁷, also driven by headcount reductions and lower professional and consulting fees.

Significant operational developments in 2025 included advancements in data analysis with upgrades to VIA and Solve software for genomic data analysis and Stratys Compute server. The AMA established a Category I CPT code for OGM for constitutional genetic disorders, effective January 1, 2026 ³⁸. CMS established a payment determination for this new CPT code and increased the payment determination for the existing Category I CPT code for OGM in hematological malignancies, effective January 1, 2026, reflecting a 47% increase compared to 2025 ³⁹. The company's installed base of OGM systems grew to 387, and 30,171 flowcells were sold ⁴⁰. OGM utility was highlighted through nine studies at the American Society of Human Genetics (ASHG) Meeting, multiple publications in Methods in Molecular Biology, and a publication comparing OGM and RNA-sequencing in cancer. The largest single-institution study evaluating OGM's clinical utility across multiple hematologic malignancies was also published. The company reported 450 peer-reviewed publications in fiscal year 2025 ⁴¹.

The company believes that its existing cash and cash equivalents and short-term investments, along with net proceeds from registered direct offerings in April 2024, July 2024, October 2024, and January 2025, the September 2025 Offering, the ATM Agreement, and the transaction under the JGB Purchase Agreement, as well as the restructuring of debt instrument redemption terms in January 2025, will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027 ⁴². However, the existing cash and cash equivalents and short-term investments will not be sufficient to achieve cash-flow break-even, and the company expects to need additional capital in the near future.

The company is primarily focused on driving adoption of OGM through its OGM systems, with a goal to streamline SV identification and enable new genomics research. A key growth area is demonstrating that OGM systems are a superior alternative to traditional techniques in constitutional genetic disorders and hematologic malignancy applications. OGM has shown superior detection sensitivity for all classes of SVs compared to karyotyping, FISH, and CMA in numerous peer-reviewed publications, offering benefits of improved assay success rates, faster time to result, and lower total cost. The AMA's establishment of a Category I CPT code for OGM in constitutional genetic disorders (code 81354), effective January 1, 2026, and the increased CLFS payment for the existing Category I CPT code for OGM in heme malignancies (code 81195), also effective January 1, 2026, are expected to accelerate broad reimbursement and establish OGM as the standard of care in professional medical society guidelines ⁴³.

Another growth vector involves continued innovation in products and technologies. The company designs its OGM systems to accommodate performance enhancements without requiring full instrument replacement, with hardware upgrades and new consumables expected to be available regularly. Software upgrades are also periodically released. The company aims to develop and refine its technologies to improve ease of use and increase sample throughput, sensitivity, and specificity of SV detection on existing installed systems. The Saphyr system images DNA at approximately 205 gigabase pairs (Gbp) per hour, while the Stratys system images between 530 and 820 Gbp per hour ⁴⁴. The company also plans to partner with industry-leading companies and laboratories to expand adoption in clinical markets, establishing additional collaborations for validating studies and expanding partnerships with clinical diagnostic companies for commercializing LDTs in the U.S. and approved tests outside the U.S.

The company's operational outlook includes a continued focus on cost-saving initiatives and maximizing the utilization of OGM systems within the current installed base, with less emphasis on new OGM system placements. This change in strategy, announced in September 2024, is expected to slow the pace of instrument revenue growth compared to historical rates and is anticipated to continue into 2026. The company expects its costs to remain high for the foreseeable future.

Planned capital allocation includes continued investment in research and development, which is considered essential for the company's long-term competitive position. The company expects to continue to spend substantial amounts of cash to commercialize its products and technologies, fund R&D programs, and execute potential strategic transactions. The company's future funding requirements will be influenced by factors such as the cost of integrating acquired businesses, market acceptance of products, and the cost and timing of establishing sales, marketing, and distribution capabilities.

Management has explicitly flagged structural headwinds and execution risks. The company's recurring losses, negative cash flows, and significant accumulated deficit have raised substantial doubt about its ability to continue as a going concern. The company will need to raise additional capital, which may not be available on acceptable terms, if at all, to fund existing operations. If unable to raise sufficient additional capital in the near term, the company may be required to further curtail operations, liquidate assets, or cease operations entirely. The company's corporate cost-saving initiatives and associated headcount reductions in 2023 and 2024 could disrupt business and may not achieve intended objectives, potentially leading to unanticipated consequences and costs. The phase-out of certain Bionano Laboratories testing services, which generated approximately $7.0 million of overall revenue in 2023 ⁴⁵, could negatively impact cash flow, financial conditions, or results of operations.

Geographic, regulatory, and macro factors identified as constraints include adverse geopolitical and macroeconomic developments such as inflation, potential future disruptions in access to bank deposits or lending commitments due to bank failures, international conflicts, and international trade policies. These factors have not had a material impact to date but could in the future. A slowdown in the Asia Pacific business, partly due to headwinds in the region and reliance on government funding for manufacturing partners, is anticipated to continue in the near term. The company is currently limited to marketing and commercialization of its products for research use only (RUO), which may limit utilization and acceptance in some settings. If the FDA ends enforcement discretion for Laboratory Developed Tests (LDTs) or determines that RUO products are medical devices, or if the company seeks to market RUO products for clinical diagnostic use, regulatory clearance or approval would be required, which would be expensive, time-consuming, and uncertain.

The company faces several material risks, including recurring net losses and negative cash flows, which raise substantial doubt about its ability to continue as a going concern. As of December 31, 2025, the company had an accumulated deficit of $719.6 million ⁴⁶, and used $16.3 million ⁴⁷ in cash from operations in 2025. The company will require additional capital to fund operations, and if not secured in the near term, it may be forced to curtail or cease operations. Corporate cost-saving initiatives and headcount reductions in 2023 and 2024 could disrupt business and may not achieve intended objectives, potentially leading to increased difficulties in implementing strategy, reduced sales force strength, and decreased employee morale. The phase-out of certain Bionano Laboratories testing services, which generated approximately $7.0 million ⁴⁸ in revenue in 2023, could negatively impact cash flow. Geopolitical and macroeconomic developments, such as inflation, potential future disruptions in access to bank deposits or lending commitments due to bank failures, international conflicts, and international trade policies, could adversely affect the business. The company relies on a single contract manufacturer for OGM systems and a limited number of manufacturers for chip consumables, posing a risk of supply disruption if these manufacturers fail. The life sciences research and diagnostic markets are highly competitive, with established and early-stage companies, and incumbent technologies like karyotyping and FISH. The company is currently limited to marketing products for research use only (RUO), and if the FDA ends enforcement discretion for Laboratory Developed Tests (LDTs) or determines RUO products are medical devices, regulatory clearance or approval would be required, which is expensive, time-consuming, and uncertain. The company's intellectual property, including over 125 issued patents ⁴⁹, may not adequately protect its competitive advantage, and it faces risks of infringement claims and challenges to patent validity.

Management's message to shareholders emphasizes a strategic shift towards maximizing the utilization of the existing installed base of OGM systems, with less emphasis on new placements, while continuing cost-saving initiatives. The company believes that with recent financings and debt restructuring, it can fund operating expenses and capital expenditure requirements into the first quarter of 2027 ⁵⁰. However, management explicitly states that existing cash and cash equivalents and short-term investments will not be sufficient to achieve cash-flow break-even, and additional capital will be needed in the near future. The three strategic priorities emphasized are: demonstrating OGM systems as a superior alternative to traditional techniques in constitutional genetic disorders and hematologic malignancy applications, accelerating broad reimbursement for OGM and establishing it as the standard of care in guidelines by professional medical societies, and continuing to innovate products and technologies.